Literature DB >> 19235168

Affinity prefractionation for MS-based plasma proteomics.

Maria Pernemalm1, Rolf Lewensohn, Janne Lehtiö.   

Abstract

The plasma proteome has proven to be one of the most challenging proteomes to profile using currently available proteomics technologies. A plethora of methodologies have been used to profile human plasma in order to discover potential biomarkers for disease and for therapy optimization. Affinity-based prefractionation coupled to MS has been shown to be one of the most successful ways to dig deeper into the plasma proteome. Depletion of high abundant plasma proteins is becoming an initial method of choice in any plasma profiling project. However, several other affinity-based enrichment methods have been published in recent years. Here we review both protein and peptide affinity prefractionation methods coupled with MS-based proteomics. Analysis of the proportion of cellular and extracellular annotated proteins of publicly available MS plasma proteomics data is performed to estimate the analytical depth of various prefractionation methods.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235168     DOI: 10.1002/pmic.200800377

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  22 in total

1.  A dual platform for selective analyte enrichment and ionization in mass spectrometry using aptamer-conjugated graphene oxide.

Authors:  Basri Gulbakan; Emir Yasun; M Ibrahim Shukoor; Zhi Zhu; Mingxu You; Xiaohong Tan; Hernan Sanchez; David H Powell; Hongjie Dai; Weihong Tan
Journal:  J Am Chem Soc       Date:  2010-11-22       Impact factor: 15.419

2.  Targeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification.

Authors:  Sibylle Hoeppe; Thomas D Schreiber; Hannes Planatscher; Andreas Zell; Markus F Templin; Dieter Stoll; Thomas O Joos; Oliver Poetz
Journal:  Mol Cell Proteomics       Date:  2010-10-20       Impact factor: 5.911

Review 3.  Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.

Authors:  Muriel De Bock; Dominique de Seny; Marie-Alice Meuwis; Jean-Paul Chapelle; Edouard Louis; Michel Malaise; Marie-Paule Merville; Marianne Fillet
Journal:  J Biomed Biotechnol       Date:  2009-12-06

4.  Depletion of abundant plasma proteins and limitations of plasma proteomics.

Authors:  Chengjian Tu; Paul A Rudnick; Misti Y Martinez; Kristin L Cheek; Stephen E Stein; Robbert J C Slebos; Daniel C Liebler
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

Review 5.  Blood-based biomarkers of Alzheimer's disease: challenging but feasible.

Authors:  Madhav Thambisetty; Simon Lovestone
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 6.  The ever-expanding myokinome: discovery challenges and therapeutic implications.

Authors:  Martin Whitham; Mark A Febbraio
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

7.  MALDI-target integrated platform for affinity-captured protein digestion.

Authors:  Asilah Ahmad-Tajudin; Belinda Adler; Simon Ekström; György Marko-Varga; Johan Malm; Hans Lilja; Thomas Laurell
Journal:  Anal Chim Acta       Date:  2013-09-11       Impact factor: 6.558

Review 8.  IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery.

Authors:  Tujin Shi; Jian-Ying Zhou; Marina A Gritsenko; Mahmud Hossain; David G Camp; Richard D Smith; Wei-Jun Qian
Journal:  Methods       Date:  2011-09-10       Impact factor: 3.608

9.  Automated platform for fractionation of human plasma glycoproteome in clinical proteomics.

Authors:  Majlinda Kullolli; William S Hancock; Marina Hincapie
Journal:  Anal Chem       Date:  2010-01-01       Impact factor: 6.986

Review 10.  Advanced proteomic liquid chromatography.

Authors:  Fang Xie; Richard D Smith; Yufeng Shen
Journal:  J Chromatogr A       Date:  2012-07-09       Impact factor: 4.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.